[Meeting Report] AMR Alliance Japan Symposium at the 94th Annual Meeting of the Japanese Association for Infectious Diseases, “The Actions Required of Us Right Now” (August 21, 2020)
date : 8/25/2020
Tags: AMR
![[Meeting Report] AMR Alliance Japan Symposium at the 94th Annual Meeting of the Japanese Association for Infectious Diseases, “The Actions Required of Us Right Now” (August 21, 2020)](https://hgpi.org/en/wp-content/uploads/sites/2/20200821.png)
On August 21, 2020, AMR Alliance Japan held a symposium as part of the 94th Annual Meeting of the Japanese Association for Infectious Diseases, entitled, “The Actions Required of Us Right Now.”
In addition to introducing the activities of AMR Alliance Japan, the symposium featured a panel of AMR Alliance Japan members, and highlighted the current actions that civil society, industry, and medical practitioners are all taking to prevent the spread of antimicrobial resistance (AMR).
Participants discussed priorities for future policy action, focusing on the topics of antimicrobial stewardship, education for the public and medical practitioners about AMR, incentive models to encourage R&D, and efforts to stabilize the supply of antimicrobials.
AMR refers to the phenomena by which bacteria become immune to antimicrobial treatments over time as those treatments are used more and more. Infectious diseases brought on by antimicrobial resistant bacteria can be difficult to treat, and can even be fatal in worst case scenarios.
It is estimated that as many as 8,000 people die every year of AMR-related causes in Japan. The problem of AMR is growing worse across the world. If current trends continue, it is projected that by 2050, as many as 10 million people could potentially die of AMR-related causes globally every year.
HGPI has taken a leading role in AMR policy within Japan as the secretariat of AMR Alliance Japan, which works with member Japanese medical societies, healthcare companies, and civil society organizations to develop and promote recommendations toward stronger AMR countermeasures. AMR Alliance Japan released broad-based recommendations for AMR policy in July 2019, and is currently actively working to realize those recommendations. More information on the Alliance and AMR can be found on the AMR Alliance Japan website at https://www.amralliancejapan.org/en/
■Program Outline
Meeting Introduction
Hiroshi Kiyota (President, Japanese Society of Chemotherapy / Professor, Department of Urology, The Jikei University Katsushika Medical Center)
Ryoji Noritake (CEO, Board Member, Health and Global Policy)
Presentation: AMR Alliance Japan’s Role and Future for the Advancement of AMR Policies
Ryoji Noritake (CEO, Board Member, Health and Global Policy)
Presentation: Initiatives of the Japan Pharmaceutical Manufacturers Association for AMR
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
Presentation: From the Perspective of Industry
Takuko Sawada (Director of the Board, Executive Vice President, Shionogi & Co., Ltd.)
Presentation: The Response to AMR by Medical Practitioners
Midori Hirai (Chair, Pharmaceutical Education Committee, The Pharmaceutical Society of Japan / Director, Japanese Red Cross Hyogo Blood Center)
Panel Discussion
Panelists:
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
Takuko Sawada (Director of the Board, Executive Vice President, Shionogi & Co., Ltd.)
Midori Hirai (Chair, Pharmaceutical Education Committee, The Pharmaceutical Society of Japan / Director, Japanese Red Cross Hyogo Blood Center)
Moderators:
Hiroshi Kiyota (President, Japanese Society of Chemotherapy / Professor, Department of Urology, The Jikei University Katsushika Medical Center)
Ryoji Noritake (CEO, Board Member, Health and Global Policy)
Top Research & Recommendations Posts
- [Policy Recommendation] Preparing for “Disaster-Level Heat” in the 2025 Basic Policy on Economic and Fiscal Management and Reform (June 9, 2025)
- [Policy Recommendation] Integrating “Planetary Health” as a Growth Strategy — Proposal for the Grand Design and Action Plan for a New Form of Capitalism (2025 Revised Edition) (June 9, 2025)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Event Report] Round Table Discussion “Understanding Menopausal Women’s Health as a Social Issue” (November 19, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Research Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Final Version) (November 14, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)
- [Policy Recommendations] HGPI Joint Input to the Zero Draft Political Declaration on NCDs and Mental Health (May 23, 2025)
Featured Posts
-
2025-07-04
[Registration Open] (Webinar) The 136th HGPI Seminar “Where We Are Now and Where We Are Going Regarding PPI in Mental Health Research: Learning from the TOGETHER Project in the Form of Co-Creation” (July 28, 2025)
-
2025-07-04
[Event Report] The HGPI Cardiovascular Disease (CVD) Control Promotion Project Online Global Symposium “Exploring the Future of CVD Control Through Policy Case Studies in the Asia-Pacific Region” (March 13, 2025)
-
2025-07-04
[HGPI Policy Column] (No. 62) From the Dementia Project “The Current State of Dementia Policy in the International Community in 2025”
-
2025-07-04
[Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)
-
2025-07-08
[Registration Open] Planetary Health Academy (Starts August 2025)